Alzheimer Disease: Rasmusen L

  Topic:  
Hints · Remembered Topics    
  Start Here  Overview  World Articles  Find Experts  Books & DVDs  Help 
 
Column View Map 2 Articles   Help
A digest of articles written 1999 and later, on the topic "Alzheimer Disease," originating from Planet Earth —» Rasmusen L.  Display:  All Citations ·  All Abstracts
1 Article Therapeutic continuity in Alzheimer's disease: switching patients to galantamine. Panel discussion: recommendations for prescribers. 2001

Morris JC, Farlow MR, Ferris SH, Kurz AF, Maelicke A, Rasmusen L, Wilkinson D, Yan B. · Department of Neurology, Washington University, St. Louis, Missouri, USA. · Clin Ther. · Pubmed #11396870 No free full text.

This publication has no abstract.

2 Article Effects of washout and dose-escalation periods on the efficacy, safety, and tolerability of galantamine in patients previously treated with donepezil: ongoing clinical trials. 2001

Rasmusen L, Yan B, Robillard A, Dunbar F. · Inova Health Research, Inc, Kelowna, British Columbia, Canada. · Clin Ther. · Pubmed #11396868 No free full text.

Abstract: With the increasing number of acetylcholinesterase inhibitors (AChEIs) being marketed for the treatment of Alzheimer's disease (AD), physicians will need protocols for discontinuing one AChEI and initiating another ("switching"). Three clinical trials have been designed to provide data that will assist in the determination of the optimal conditions for switching patients from donepezil (the most widely prescribed AChEI) to galantamine (the most recently approved AChEI). The main objective of these studies is to investigate the effects of different washout periods (0 to 7 days) and dose-escalation schedules (fixed, fast vs slow) on the efficacy, safety, and tolerability of galantamine in patients with AD who were previously taking donepezil. The duration of the trials ranges from 12 to 52 weeks, and the last trial is expected to end in May 2002. No conclusions can yet be drawn from these ongoing trials, but the results should be helpful in establishing guidelines for physicians to use when switching patients with AD from donepezil to galantamine.